Outlook Therapeutics · ONS-5010 · 2023 – 2026
Did the FDA ask Outlook for another clinical trial, or for confirmatory evidence?
Outlook's filings describe the FDA's request in different terms: confirmatory evidence of efficacy, additional well-controlled clinical evidence, evidence of an unstated type, and, in June 2026, no additional trials.
EphemerisX Research · Published · 5 source documents · 1 min read
Short answer
Outlook's own filings use different words for what the FDA asked for. The August 2025 press release says confirmatory evidence of efficacy; the 10-K's risk summary says additional well-controlled clinical evidence; the December 2025 release says the FDA had not said what type of evidence would do. In June 2026 the company reports that additional trials are not required.
What the evidence shows
After the 2023 letter, according to the 10-K, the FDA required the completion of an additional adequate and well-controlled clinical trial
10-K · Dec 19, 2025.
How the filings describe the request, in sequence, is set out below; each line quotes an Outlook filing.
Not in this record: the FDA's own text of either 2025 letter's deficiency (each letter's first page has no text layer) or the FDA's dispute resolution decision. How the request was resolved: How did evidence the FDA said did not alter its conclusion come to establish substantial evidence?
What changed
August 28, 2025 press release: it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010
8-K · Sep 2, 2025.
December 2025 10-K, summary of risk factors: the FDA indicated that additional well-controlled clinical evidence would be required
10-K · Dec 19, 2025.
December 31, 2025 press release, on the second letter: the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application, however the FDA has not indicated what type of confirmatory evidence would be acceptable
8-K · Jan 2, 2026.
March 2026 risk factors: it is possible that we may need to conduct additional clinical and/or non-clinical studies of ONS-5010 in order to satisfy the FDA’s requirements
8-K · Mar 16, 2026.
June 1, 2026 press release, after the appeal: the FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), therefore additional trials are not required
8-K · Jun 1, 2026.
Follow the thread
- Was the FDA's August 2025 letter its first Complete Response Letter on ONS-5010?2023: an additional well-controlled trial required
- What changed between the FDA's August and December 2025 letters?“Has not indicated what type” of evidence
- What happened after the FDA's December 2025 letter?March 2026: the “third” letter
This investigation connects to
- What happens after a second FDA Complete Response Letter?Cross-investigation · Divergent outcome · with Aldeyra Therapeutics, CorMedix, Replimune, Verrica Pharmaceuticals
- How did two programs move forward after repeat FDA letters without running a new trial?Cross-investigation · Comparable evidence · with Replimune
- When is one trial enough? How the FDA weighed the evidence in three programsCross-investigation · Comparable evidence · with Aldeyra Therapeutics, Replimune
The documents, by date
The passages quoted
Outlook Therapeutics Form 8-K, filed September 2, 2025
The CRL included only one deficiency, for a lack of substantial evidence of effectiveness. In the CRL, the FDA advised that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. Additionally, the FDA reiterated that NORSE TWO met its primary endpoint for effectiveness.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
We received a second Complete Response Letter from the FDA in August 2025 with respect to our resubmitted BLA for ONS-5010/LYTENAVA for wet AMD in the United States, in which the FDA concluded that the application did not contain substantial evidence of effectiveness and indicated that additional well-controlled clinical evidence would be required.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
At subsequent Type A meetings with the FDA, we learned that the FDA required the completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD.Open at the source →
Outlook Therapeutics Form 8-K, filed January 2, 2026
In the CRL, the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application, however the FDA has not indicated what type of confirmatory evidence would be acceptable.Open at the source →
Outlook Therapeutics Form 8-K, filed March 16, 2026
Moreover, on December 31, 2025, we reported that we had received a third Complete Response Letter, or CRL, with respect to our Biologics License Application, or BLA, for ONS-5010, and the U.S. Food and Drug Administration, or FDA, has again recommended that confirmatory evidence of efficacy be submitted to support the application. However, the FDA did not indicate in the CRL what type of confirmatory evidence would be acceptable, and it is possible that we may need to conduct additional clinical and/or non-clinical studies of ONS-5010 in order to satisfy the FDA’s requirementsOpen at the source →
Outlook Therapeutics Form 8-K, filed June 1, 2026
As previously announced, Outlook Therapeutics successfully appealed the December 2026 Complete Response Letter (CRL) related to the ONS-5010 Biologics License Application reviewed by the FDA. In their decision, the FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), therefore additional trials are not required.Open at the source →